Whole Genome Sequencing in the Detection of Rare Undiagnosed Genetic Diseases in Children in China

Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (Other)
Overall Status
Unknown status
CT.gov ID
NCT03424772
Collaborator
(none)
100
14
13.4
7.1
0.5

Study Details

Study Description

Brief Summary

To assess the indications and diagnostic efficiency of whole genome sequencing (WGS) in pediatric patients with unexplained intellectual disability/developmental delay, multiple congenital abnormalities and other rare and undiagnosed diseases

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Whole genome sequencing

Detailed Description

This project will recruit 100 rare, undiagnosed pediatric genetic disease families (core families: patients, patients' parents, immediate family members such as brothers and sisters, all of them can be enrolled whether they have disease or not, so generally 3, for a few cases 4 or 5) all over the country. The expert team will review the clinical materials, the molecular team will review the experimental process, and the bioinformatics team will review the chip, the analysis of whole exome sequencing data and screen the samples all over the country;

Whole-genome sequencing of 100 rare, undiagnosed pediatric genetic disease families (Illumina NovaSeq High-throughput Sequencer);

The study will provide preliminarily performance data on the comparison of whole exome data and whole genome data. In addition, it will generate the Chinese Consensus on Clinical Applications of Whole-genome sequencing in the Diagnosis of Birth Defects and Undiagnosed Rare Genetic Diseases in Children based on the statistical analysis of clinical phenotype and genotype association, which could guide the clinical application of pediatrics, laboratory testing and reporting.

Construction of the Chinese detection genome database of genetic disease

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
100 participants
Observational Model:
Family-Based
Time Perspective:
Prospective
Official Title:
Clinical Collaborative Research of Whole Genome Sequencing in the Detection of Rare Undiagnosed Genetic Diseases in Children in China
Actual Study Start Date :
Jan 18, 2018
Anticipated Primary Completion Date :
Dec 1, 2018
Anticipated Study Completion Date :
Mar 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Patients with unexplained DD/ID

Whole genome sequencing will be performed on pediatric patients with unexplained developmental delay(DD)/intellectual disability(ID), multiple congenital abnormalities and other rare and undiagnosed diseases.

Diagnostic Test: Whole genome sequencing
WGS will be performed for the trio

Outcome Measures

Primary Outcome Measures

  1. Number of diagnosed families [1 year]

    Families with rare and undiagnosed pediatric genetic disease will be benefitted by WGS.

Secondary Outcome Measures

  1. Numbers of pathogenic variants in different variation types [1 year]

    WGS would have the potential to detect different types of genetic alterations, such as structure variations, point mutation, small insertion/deletion, trinucleotide repeat, etc. Some types could not be identified by exome sequencing and chromosomal microarray. The numbers of the pathogenic variants in these types will be calculated to examine the benefit of WGS.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A to 18 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Intelligence tests results of less than 40 (patients <3 years old using the Gesell Developmental Scale for screening; patients of 3-6 years old using Little Wechsler Intelligence Scale for screening; patients >6 years old using Old Wechsler Intelligence Scale for screening).

  2. Neurodevelopmental defects can be expressed as mental retardation, motor development retardation, language delay, epilepsy, etc. May have or not have Multiple congenital abnormalities, families with more than one affected patient will be enrolled priority

  3. Families went through at least one of the high throughput technology(WES or CMA) and receive the negative result

Exclusion Criteria:
  1. Intellectual disability caused by pregnancy, perinatal infection, ischemia, and hypoxia and other non-hereditary causes,

  2. Obvious genetic metabolic diseases (such as different types of genetic metabolic diseases, bone disease, fragile X syndrome, etc.);

Contacts and Locations

Locations

Site City State Country Postal Code
1 Peking Union Medical College Hospital Beijing Beijing China 100005
2 Children's Hospital, Capital Institute of Pediatrics Beijing Beijing China 100020
3 Department of Pediatrics, Peking University First Hospital Beijing Beijing China 100034
4 The Maternal & Child Health Hospital, The Children's Hospital, The Obstetrics & Gynecology Hospital of Guangxi Zhuang Autonomous Region Nanning Guangxi China 530005
5 The Maternal and Child Health Hospital of Hunan Province Changsha Hunan China 410008
6 Xiangya Hospital, Central-south University / Hunan Jiahui genetics hospital Changsha Hunan China 410008
7 Hunan Children's Hospital Changsha Hunan China 410011
8 Nanjing maternal and children hospital Nanjing Jiangsu China 210004
9 Ruijin Hospital affiliated to Shanghai Jiaotong University Shanghai Shanghai China 200025
10 Children's Hospital of Shanghai Shanghai Shanghai China 200041
11 Shanghai Institute for Pediatric Research Shanghai Shanghai China 200092
12 Xin Hua Hospital, Shanghai Jiaotong University School of Medicine Shanghai Shanghai China 200092
13 Shanghai Children's Medical Center Shanghai Shanghai China 201712
14 Wenzhou Central Hospital Wenzhou Zhejiang China 325099

Sponsors and Collaborators

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Investigators

  • Principal Investigator: Yongguo Yu, MD, PhD, Specify Unaffiliated

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Yongguo Yu, Associate chief physician, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
ClinicalTrials.gov Identifier:
NCT03424772
Other Study ID Numbers:
  • XH-18-001
First Posted:
Feb 7, 2018
Last Update Posted:
Feb 8, 2018
Last Verified:
Feb 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 8, 2018